TITLE

Review: Lorazepam provides the best control for status epilepticus

PUB. DATE
March 2006
SOURCE
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p35
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study which reveals that lorazepam provides the best control for status epilepticus (SE). Randomized or quasi-randomized controlled trials were conducted that compared any anticonvulsant drug with placebo or another anticonvulsant drug in patients with premonitory, early stage, established or refractory SE. Superior results were seen with intravenous (IV) lorazepam for cessation of seizures and reducing risk for SE that required a second drug. IV diazepam was better than placebo for reducing death, continuation of seizures, SE and ventilatory support.
ACCESSION #
20297590

 

Related Articles

  • Eslicarbazepine Acetate: A Review of Its Use as Adjunctive Therapy in Refractory Partial-Onset Seizures. Keating, Gillian // CNS Drugs;Jul2014, Vol. 28 Issue 7, p583 

    Eslicarbazepine acetate (Aptiom, Zebinix) is approved for the adjunctive treatment of partial-onset seizures in adults aged ≥18 years. Adjunctive therapy with oral eslicarbazepine acetate 800 or 1,200 mg once daily was associated with a significantly lower standardized seizure frequency...

  • Spotlight on Levetiracetam in Epilepsy. Lyseng-Williamson, Katherine A. // CNS Drugs;2011, Vol. 25 Issue 10, p901 

    Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy...

  • Safety profile of Bilastine: 2nd generation h1-antihistamines. SCAGLIONE, F. // European Review for Medical & Pharmacological Sciences;Jan2013, Vol. 17 Issue 1, p1999 

    Bilastine is a new H1 antagonist with no sedative side effects, no cardiotoxic effects, and no hepatic metabolism. In addition, bilastine has proved to be effective for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. Pharmacological studies have shown that bilastine is...

  • Ethical issues of using placebo in antiepileptic drugs trials in Asia. Byung In Lee // Neurology Asia;2010 Supplement 1, Vol. 15 Issue S1, p29 

    Any human trials should be designed and conducted within the ethical framework of the "Declaration of Helsinki" stating that any new agent must be tested against standard, proven therapies when available. In the clinical development of antiepileptic drugs, a double-blinded, placebo-controlled...

  • Neuroprotection in epilepsy: the role of antiepileptic drugs. Kimiskidis, Vasileios // Annals of General Psychiatry;2008 Supplement 1, Vol. 7, Special section p1 

    During the last 15 years, accumulating experimental and clinical evidence suggested that the epileptic brain may undergo significant modifications as a result of recurrent seizures or due to the underlying seizure etiology. This concept of epilepsy as an evolving neurodegenerative process is...

  • Managing the first seizure: Sharing the decision with the patient result in better care. Bharucha, Nadir // Neurology India;Dec2006, Vol. 54 Issue 4, p350 

    The article comments on the paper "Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: A randomized controlled trial" in the December 2006 issue of "Neurology India." The principles utilized to counsel patients about the risks of seizure recurrence and...

  • Treating Newly Diagnosed Epilepsy: The Canadian Choice. Burneo, J. G.; McLachlan, R. S. // Canadian Journal of Neurological Sciences;May2007, Vol. 34 Issue 2, p230 

    Background: Choosing an antiepileptic medication to treat a patient with epilepsy can be a complicated process during which the treating physician must base her or his decision on efficacy and safety of each of many available drugs. The lack of comparative studies between medications is one of...

  • Stiripentol Chiron, Catherine // Neurotherapeutics;Jan2007, Vol. 4 Issue 1, p123 

    Summary: Stiripentol (STP) is a new antiepileptic compound made by Biocodex. It recently proved to increase the GABAergic transmission in vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19 in...

  • Anticonvulsant Action of a New Analogue of Allopregnanolone in Immature Rats. Mareš1, P.; Kubová, H.; Kasal, A. // Physiological Research;2010, Vol. 59 Issue 2, p305 

    Neuroactive steroids represent potential antiepileptic drugs. We tested a newly synthesized analogue of allopregnanolone 3α- hydroxy-21ξ,22-oxido-21-homo-5α-pregnan-20-on (HOHP) against two types of pentylenetetrazol-induced seizures (100 mg/kg s.c.) in 12- and 25-day-old rats....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics